四种肿瘤标志物联合检测在肺癌诊断、治疗检测及判断预后的价值

Value of serum CEA,CYFRA21-1,NSE and CA125 in lung cancer diagnosis,treatment and prognosis

目的探讨血清癌胚抗原(CEA)、细胞角质蛋白(CYFRA21-1)和神经烯醇化酶(NSE)、糖类抗原125(CA125)对肺癌诊断、治疗检测及预后评估的价值。方法采取血清标本46例,其中腺癌14例、鳞癌23例、小细胞癌9例,肺部良性病变32例。结果 CEA、CYFRA21-1、NSE和CA125在肺癌组的敏感性分别为47.83%、47.83%、52.17%和56.52%。其中CEA对腺癌的敏感性为78.57%,CYFRA21-1对鳞癌的敏感性为60.86%,NSE对小细胞癌的敏感性为88.89%,均明显高于肺部良性病变对照组。将4项联合检测,高于4项单检时的敏感性。肺癌组化疗有效者四项水平明显下降,病情稳定和进展四者水平无变化。结论 CEA、CYFRA21-1、NSE分别对腺癌、鳞癌及小细胞癌的诊断有一定的意义。将CEA、CYFRA21-1、NSE和CA125 4项联检可提高肺癌的诊断率,亦可作为肺癌的疗效检测和预后评估方面有价值的指标。

Objective To determine the clinical value of four tumor markers： serum CEA,Cyfra21-1,NSE and CA125 in the diagnosis of lung cancer.Methods The serum samples of 46 patients were evaluated： including 14 with denocarcinomas,23 with suamous cell carcinomas,9 with small-cell lung cancer（SCLC）,and 32 with benign pulmonary disease.Result The sensitivity of CEA,Cyfra21-1,NSE and CA125 over all are 47.83%,47.83%,52.17%和56.52%.After chemotherapy,the serum levels of the markers were decreased significantly in the CR and PR patients,but increased or not changed in patients with advanced disease or metastases.The combined measurement of CEA,Cyfra21-1,NSE and CA125 could increase diagnosis value of lung cancer.Conclusion Individually CEA,Cyfra21-1,NSE could be the useful in diagnosis of adnocarcinoma,squmous cell carcinoma and SCLC.The combined evaluation of CEA,Crfra21-1,NSE and CA125 could increase their diagnosis.The four markers could also be valuable for the evaluation of therapeutic efficacy and the determination of a prognosis.